# Study of Phosphate Levels in Patients With Chronic Kidney Disease

> **NCT00824460** · PHASE2 · COMPLETED · sponsor: **Vifor Pharma** · enrollment: 154 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** 1.25 g PA21 (250 mg iron)
- **DRUG:** 5.0 g PA21 (1,000 mg iron)
- **DRUG:** 7.5 g PA21 (1,500 mg iron)
- **DRUG:** 10.0 g PA21 (2,000 mg iron)
- **DRUG:** 12.5 g PA21 (2,500 mg iron)
- **DRUG:** Sevelamer hydrochloride

## Key facts

- **NCT ID:** NCT00824460
- **Lead sponsor:** Vifor Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-10
- **Final completion:** 2010-03
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2014-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00824460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00824460, "Study of Phosphate Levels in Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00824460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*